What is the Lumipulse test for Alzheimer’s disease? In May, the U.S. Food and Drug Administration permitted marketing of the Lumipulse (G B-Amyloid Ratio [1-42/1-40]) test to Fujirebio Diagnostics, ...
POTOMAC, Md.--(BUSINESS WIRE)-- IGC Pharma, Inc. (NYSE American: IGC) ("IGC" or the "Company") today announced encouraging preclinical results in an Alzheimer’s mouse model demonstrating the potential ...
Findings showed 91.7% of patients with positive results using Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio test had amyloid plaques based on PET scan or CSF test results. The Food and Drug ...
The FDA has approved the first blood test to detect signs of Alzheimer’s disease, marking a major step toward easier diagnosis. The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio test identifies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results